A Prospective Observational Study to Estimate the Incidence of Febrile Neutropenia (FN) Among Subjects with Non-myeloid Malignancies at High Risk for FN and Receiving Neulasta® (pegfilgrastim) Onpro® kit or Other Physician Choice Options for Prophylaxis of FN (Amgen 20170758)

Study Details

This is a multicenter, prospective, observational cohort study in subjects receiving myelosuppressive chemotherapy for a non-myeloid malignancy and are considered at high risk for developing FN.

ClinicalTrials.gov NCT number
NCT not applicable

Principal Investigators

  • Steve Lo, MD
Sponsor(s)
Amgen
Contact
Ian Goff at 203-358-8879
or officeofresearch@stamhealth.org

Location

  • Bennett Cancer Center
    One Hospital Plaza
    Stamford, CT 06902
    Main: 203-276-2695